Tuesday, September 22, 2020 5:33:12 PM
Interesting debate between folks I respect and pay heed to.. Just a simple question for you folks..
1.. Do ANY of you think Our HIV BLA could be accepted by DECEMBER 2021..??
2.. If YES..Do you doubt CYDY stock price could be at least 10 dollars at that instance..??
3.. Selling CYDY at 3.50 ..What stock would get you close to 10 dollars..or approximately 3 times the return in a matter of 15 months..??
MY CONCERN HONESTLY IS..
1.. We HAVE to do a Phase 3.. Mild to Moderate Corona Trial.. LERONLIMAB did not just perform WELL..It performed BRILLIANTLY..in OUR Phase 2 Trial ..The problem was in the Protocol..NOT LERONLIMAB..
When you enroll ASYMPTOMATIC Corona patients ..With a News 2 score of ZERO..Give them A placebo..AND the News 2 Score remains ZERO..WHAT THE HELL ARE YOU DOING..?? How can LERONLIMAB compete against THAT..?? Leronlimab is not an aphrodisiac or HAPPY PILL..Give it a level playing field..One which has SICK PATIENTS..THEN watch it PERFORM..!!!
2.. We MUST NOT DO A LONG HAULERS TRIAL..
These patients include those with Strokes..Pulmonary Fibrosis..Renal impairments..Not just folks exhibiting Fatigue..Headaches..Myalgias..Insomnia..Depression etc..
The long term outcomes in these patient’s will be determined by their PREEXISTING CONDITIONS..ie Diabetes..Hypertension..Hypercholesterolemia..Smoking Habits..AND access to Health Care..
LERONLIMAB will be blamed for a failure..Not of it’s own doing..!!! There are TOO MANY VARIABLES..for even OUR CHAMPION to control.. !!!
Look at a patient s/p a STOKE..!!! Many of these patients have ABNORMAL CARDIAC CT’s that show a decrease in function..Even though the heart was supposedly NOT affected by the Corona Virus in the first instance...Leronlimab May prevent a second stroke ..Due to its effect on the blood vessels..But CANNOT stop a clot forming in a hypokinetic heart..and embolising to the brain..Thereby negating it’s efficacy..
LETS NOT ABUSE LERONLIMAB A SECOND TIME..Give it a level playing field..And I know it’ll LAP the field..!!!
Here’s hoping Grip it and RIP it..AND..Saltz.. rejoin OUR efforts soon.. to get LERONLIMAB..TO THE WORLD..!!
IMHO..
1.. Do ANY of you think Our HIV BLA could be accepted by DECEMBER 2021..??
2.. If YES..Do you doubt CYDY stock price could be at least 10 dollars at that instance..??
3.. Selling CYDY at 3.50 ..What stock would get you close to 10 dollars..or approximately 3 times the return in a matter of 15 months..??
MY CONCERN HONESTLY IS..
1.. We HAVE to do a Phase 3.. Mild to Moderate Corona Trial.. LERONLIMAB did not just perform WELL..It performed BRILLIANTLY..in OUR Phase 2 Trial ..The problem was in the Protocol..NOT LERONLIMAB..
When you enroll ASYMPTOMATIC Corona patients ..With a News 2 score of ZERO..Give them A placebo..AND the News 2 Score remains ZERO..WHAT THE HELL ARE YOU DOING..?? How can LERONLIMAB compete against THAT..?? Leronlimab is not an aphrodisiac or HAPPY PILL..Give it a level playing field..One which has SICK PATIENTS..THEN watch it PERFORM..!!!
2.. We MUST NOT DO A LONG HAULERS TRIAL..
These patients include those with Strokes..Pulmonary Fibrosis..Renal impairments..Not just folks exhibiting Fatigue..Headaches..Myalgias..Insomnia..Depression etc..
The long term outcomes in these patient’s will be determined by their PREEXISTING CONDITIONS..ie Diabetes..Hypertension..Hypercholesterolemia..Smoking Habits..AND access to Health Care..
LERONLIMAB will be blamed for a failure..Not of it’s own doing..!!! There are TOO MANY VARIABLES..for even OUR CHAMPION to control.. !!!
Look at a patient s/p a STOKE..!!! Many of these patients have ABNORMAL CARDIAC CT’s that show a decrease in function..Even though the heart was supposedly NOT affected by the Corona Virus in the first instance...Leronlimab May prevent a second stroke ..Due to its effect on the blood vessels..But CANNOT stop a clot forming in a hypokinetic heart..and embolising to the brain..Thereby negating it’s efficacy..
LETS NOT ABUSE LERONLIMAB A SECOND TIME..Give it a level playing field..And I know it’ll LAP the field..!!!
Here’s hoping Grip it and RIP it..AND..Saltz.. rejoin OUR efforts soon.. to get LERONLIMAB..TO THE WORLD..!!
IMHO..
Recent CYDY News
- CytoDyn Announces First Patient Dosed in Expanded Access Program for Leronlimab in Triple-Negative Breast Cancer • GlobeNewswire Inc. • 04/27/2026 12:30:00 PM
- CytoDyn to Host Investor Webcast • GlobeNewswire Inc. • 04/23/2026 12:30:00 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 04/22/2026 09:21:50 PM
- CytoDyn Presents New Leronlimab Data in Metastatic Colorectal Cancer at AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/22/2026 12:30:00 PM
- CytoDyn Completes Enrollment in Phase 2 Metastatic Colorectal Cancer Study • GlobeNewswire Inc. • 04/21/2026 08:10:00 PM
- CytoDyn Presents New Leronlimab Data in Metastatic Triple-Negative Breast Cancer at AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/20/2026 12:30:00 PM
- CytoDyn to Present at the AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/14/2026 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 04/08/2026 09:15:18 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/08/2026 12:30:28 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/25/2026 09:16:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:24:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:23:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:22:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:21:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:57 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/24/2026 09:15:24 PM
- CytoDyn Presents at AACR Special Conference in Cancer Research: Brain Cancer • GlobeNewswire Inc. • 03/24/2026 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/09/2026 09:15:18 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/05/2026 01:35:02 PM
- CytoDyn Closes $17.5 Million Financing to Fund Continued Development of Leronlimab • GlobeNewswire Inc. • 03/05/2026 01:30:00 PM
- CytoDyn Presents Novel CCR5 Inhibition Mechanisms and Long-Term Survival Signals for Leronlimab in Metastatic Breast Cancer at AACR Immuno-Oncology Conference • GlobeNewswire Inc. • 02/20/2026 01:30:00 PM
- CytoDyn Announces Funding and Initiation of Expanded Access Program for Patients with Triple-negative Breast Cancer • GlobeNewswire Inc. • 01/27/2026 01:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 01/09/2026 10:15:22 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 01/09/2026 01:30:45 PM
